Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): Results of a multi-center randomized phase II AIO trial.

Alwin Krämer(Heidelberg University), Stefan Kasper(Essen University Hospital), Gunnar Folprecht, Katharina Schütte(Marienhospital Stuttgart), Ralf‐Dieter Hofheinz(University of Mannheim), Carsten Bokemeyer(Universität Hamburg), Viktor Grünwald(Deutsche Schmerzgesellschaft), Alexander Stein(Universität Hamburg), H. Löffler(University of Mannheim), Claus‐Henning Köhne(Klinikum Oldenburg), Albrecht Kretzschmar(Roche (Switzerland)), Michael Stahl(Kliniken Essen-Mitte), G. Huebner(Westpfalz Klinikum)
Journal of Clinical Oncology
May 20, 2019
10.1200/jco.2019.37.15_suppl.4120
Cited by 2

Related Papers

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
|Annals of Internal Medicine|2020|2.4k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k